Patients 70 years with untreated , metastatic NSCLC were randomized to Erlotinib ( E ) , 150 mg/day or Carboplatin ( AUC5 ) plus Vinorelbine ( 25mg/m ( 2 ) on days 1 and 8 ) every three weeks ( CV ) .